Table 3

Main Angiographic Characteristics

Study (Ref. #)SFAPopliteal ± SFABTK ± SFA–PoplitealDe NovoPrevious PBISRLesion Length (cm)Total OcclusionBailout Stenting
DCB vs. PB
Biolux P-I (25)80.9 (55)17.6 (8)5.9 (4)41.7 (25)58.3 (35)0 (0)6.038.2 (26)6.7 (2) vs. 26.7 (8)
FAIR (8)89.9 (107)10.1 (12)0 (0)0 (0)0 (0)100 (119)8.228.6 (34)1.6 (1) vs. 7.0 (4)
FemPac (26)74.7 (65)16.1 (14)9.2 (8)65.5 (57)27.6 (24)6.9 (6)4.316.1 (87)8.9 (4) vs. 14.3 (6)
IN.PACT SFA (27,30)93.1 (311)6.9 (23)0 (0)94.9 (314)5.1 (17)0 (0)8.923.1 (77)7.3 (16) vs. 12.6 (14)
LEVANT I (28)93.1 (94)6.9 (7)0 (0)89.1 (90)10.9 (11)0 (0)8.041.6 (42)28.6 (14) vs. 50.0 (26)
LEVANT 2 (6)91.0 (433)9.0 (43)0 (0)85.1 (405)14.9 (71)0 (0)6.321.0 (100)2.5 (8) vs. 6.9 (11)
PACIFIER (29)100 (91)100 (91)0 (0)75.8 (69)9.9 (9)14.3 (13)6.830.8 (28)20.5 (9) vs. 34.0 (16)
THUNDER (7,31)66.7 (68)33.3 (34)0 (0)66.7 (68)19.6 (20)13.7 (14)7.426.5 (27)4.2 (2) vs. 22.2 (12)

BR = binary restenosis; BTK = below-the-knee; ISR = in-stent restenosis; SFA = superficial femoral artery; other abbreviations as In Tables 1 and 2.

Values are % (n) unless otherwise indicated. All within-trial differences were not significant unless otherwise reported.

  • Significant difference (Biolux P–I, p = 0.04; LEVANT 2, p = 0.02; THUNDER, comparing also the third arm, which was excluded in this meta–analysis, p = 0.01).

  • The reported numbers derives from the combination of provisional and bailout stenting. The difference in bailout stenting (“Balloon–only” group) was statistically significant (p = 0.05).

  • Median.